Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics today released preliminary fourth quarter financial results for its RosettaGX Reveal thyroid nodule assay, reporting a 38 percent increase in test sales over the third quarter.

For the three-month period ended Dec. 31, Reveal generated preliminary revenues of $390,000 versus $282,000 in the third quarter. During the fourth quarter, Rosetta received 423 orders for the test compared with 305 units received in the previous quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.